Association of the Fcγ receptor IIA-R/R131 genotype with myasthenia gravis in Dutch patients

Journal of Neuroimmunology

Volumn 144, Issue 1-2, 2003, Pages 143-147

  Van Der Pol, W L ^a   Jansen, M D ^a   Kuks, J B M ^b   De Baets, M ^c   Leppers Van De Straat, F G J ^a   Wokke, J H J ^a   Van De Winkel, J G J ^a   Van Den Berg, L H ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^c MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Fc R; Myasthenia gravis; Polymorphism

Indexed keywords

FC RECEPTOR;

ADULT; AGED; ALLELE; ARTICLE; CHILD; CONFIDENCE INTERVAL; CONTROLLED STUDY; FEMALE; GENE FUNCTION; GENETIC ASSOCIATION; GENETIC HETEROGENEITY; GENETIC MARKER; GENETIC POLYMORPHISM; GENETIC RISK; GENETIC SUSCEPTIBILITY; GENOTYPE; HUMAN; IMMUNOMODULATION; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MALE; MYASTHENIA GRAVIS; PRIORITY JOURNAL;

EID: 0142258018     PISSN: 01655728     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jneuroim.2003.08.043     Document Type: Article

References (42)

1. Bergoffen J., Zmijevski C.M., Fischbeck K.H. Familial autoimmune myasthenia gravis. Neurology. 44:1994;551-554.
2. Bredius R.G.M., Fijen C.A.P., de Haas M., Kuijper E.J., Weening R.S., van de Winkel J.G.J., Out T.A. Role of the neutrophil Fcγ RIIa (CD32) and the Fcγ RIIIb (CD16) polymorphic forms in phagocytosis of human IgG1- and IgG3-opsonized bacteria and erythrocytes. Immunology. 83:1994;624-630.
3. Carlsson L.E., Santoso S., Baurichter G., Kroll H., Papenberg S., Eichler P., Westerdaal N.A., Kiefel V., van de Winkel J.G., Greinacher A. Heparin-induced thrombocytopenia: new insights into the impact of the FcγRIIa-131R-H polymorphism. Blood. 92:1998;1526-1531.
4. Clynes R., Maizes J.S., Guinamard R., Ono M., Takai T., Ravetch J.V. Modulation of immune complex-induced inflammation in vivo by the coordinate expression of activation and inhibitory Fc receptors. J. Exp. Med. 189:1999;179-185.
5. Compston D.A., Vincent A., Newsom-Davis J., Batchelor J.R. Clinical, pathological, HLA antigen and immunological evidence for disease heterogeneity in myasthenia gravis. Brain. 103:1980;579-601.
6. De Baets M., Stassen M.H.W. The role of antibodies in myasthenia gravis. J. Neurol. Sci. 202:2002;5-11.
7. De Haas M., Kleijer M., van Zwieten R., Roos D., von dem Borne A.E.G.Kr. Neutrophil FcγRIIIb deficiency, nature and clinical consequences: a study of 21 individuals from 14 families. Blood. 86:1995;2403-2413.
8. Dijstelbloem H.M., Scheepers R.H.M., Oost W.W., Stegeman C.A., Van der Pol W-L., Sluiter W.J., Kallenberg C.G.M., Van de Winkel J.G.J., Cohen Tervaert J.W. Fcγ receptor polymorphisms in Wegener's granulomatosis: risk factors for disease relapse. Arthritis Rheum. 42:1999;1823-1827.
9. Dijstelbloem H.M., Bijl M., Fijnheer R., Scheepers R.H.M., Oost W.W., Jansen M.D., Sluiter W.J., Limburg P.C., Derksen R.H.W.M., van de Winkel J.G.J., Kallenberg C.G.M. Fcγ receptor polymorphisms in systemic lupus erythematosus. Association with disease and in vivo clearance of immune complexes. Arthritis Rheum. 43:2000;2793-2800.
10. Dondi E., Gajdos P., Bach J.F., Garchon H.J. Association of Km3 allotype with increased serum levels of autoantibodies against muscle acetylcholine receptor in myasthenia gravis. J. Neuroimmunol. 51:1994;221-224.
11. Duits A.J., Bootsma H., Derksen R.H.W.M., Spronk P.E., Kater L., Kallenberg C.G.M., Capel P.J.A., Westerdaal N.A.C., Spierenburg G.Th., Gmelig-Meyling F.H.J., van de Winkel J.G.J. Skewed distribution of IgG Fc receptor IIa (CD32) polymorphism is associated with renal disease in systemic lupus erythematosus patients. Arthritis Rheum. 39:1995;1832-1836.
12. Fijen C.A.P., Bredius R.G.M., Kuijper E.J. Polymorphism of IgG Fc receptors in meningococcal disease. Ann. Intern. Med. 119:1993;636.
13. Garchon H.J., Djabiri F., Viard J.P., Gajdos P., Bach J.F. Involvement of human muscle acetylcholine receptor α-subunit gene (CHRNA) in susceptibility to myasthenia gravis. Proc. Natl. Acad. Sci. 91:1994;4668-4672.
14. Giraud M., Beaurain G., Yamamoto A.M., Eymard B., Tranchant C., Gajdos P., Garchon H.J. Linkage of HLA to myasthenia gravis and genetic heterogeneity depending on anti-titin antibodies. Neurology. 57:2001;1555-1560.
15. Hjelmström P., Giscombe R., Lefvert A.K., Pirskanen R., Kockum I., Landin-Olsson M., Sanjeevi C.B. Polymorphic amino acid domains of the HLA-DQ molecule are associated with disease heterogeneity in myasthenia gravis. J. Neuroimmunol. 65:1996;125-131.
16. Hjelmström P., Peacock C.S., Giscombe R., Pirskanen R., Lefvert A.K., Blackwell J.M., Sanjeevi C.B. Polymorphism in tumor necrosis factor genes associated with myasthenia gravis. J. Neuroimmunol. 88:1998;137-143.
17. Hoch W., McConville J., Helms S., Newsom-Davis J., Melms A., Vincent A. Auto-antibodies to the receptor tyrosine kinase MuSK in patients with myasthenia gravis without acetylcholine receptor antibodies. Nat. Med. 7:2001;365-368.
18. Huang D., Liu L., Noren K., Xia S., Trifunovic J., Pirskanen R., Lefvert A.K. Genetic association of Ctla-4 to myasthenia gravis with thymoma. J. Neuroimmunol. 88:1998;192-198.
19. Huang D., Pirskanen R., Hjelmstrom P., Lefvert A.K. Polymorphisms in IL-1β and IL-1 receptor antagonist genes are associated with myasthenia gravis. J. Neuroimmunol. 81:1998;76-81.
20. Huang D., Zheng C., Giscombe R., Matell G., Pirskanen R., Lefvert A.K. Polymorphisms at -174 and in the 3′ flanking region of interleukin-6 (IL-6) gene in patients with myasthenia gravis. J. Neuroimmunol. 101:1999;197-200.
21. Huizinga T.W.J., Kleijer M., Tetteroo P.A.T., Roos D., von dem Borne A.E.G.Kr. Biallelic neutrophil NA-antigen system is associated with a polymorphism on the phospho-inositol-linked Fcγ receptor III (CD16). Blood. 75:1990;213-217.
22. Karassa F.B., Trikalinos T.A., Ioannidis J.P.A. Role of Fcγ receptor IIa polymorphism in susceptibility to systemic lupus erythematosus and lupus nephritis. Arthritis Rheum. 46:2002;1563-1571.
23. Koene H.R., Kleijer M., Algra J., Roos D., von dem Borne A.E.G.Kr., de Haas M. FcγRIIIa-158V/F polymorphism influences the binding of IgG by NK cell FcγRIIIa, independently of the Fcγ RIIIa-48L/R/H phenotype. Blood. 90:1997;1109-1114.
24. Leppers-van de Straat F.G.J., Van der Pol W.-L., Jansen M.D., Sugita N., Yoshie H., Kobayashi T., Van de Winkel J.G.J. A novel PCR-based method for direct Fcγ Receptor IIIA (CD16) allotyping. J. Immunol. Methods. 242:2000;127-132.
25. Melms A., Weissert R., Klinkert W.E., Schalke B.C., Tzartos S., Werkerle H. Specific immune complexes augment in vitro acetylcholine receptor-specific T-cell proliferation. Neurology. 43:1993;583-588.
26. Mendell J.R., Garcha T.S., Kissel J.T. The immunopathogenic role of complement in human muscle disease. Curr. Opin. Neurol. 9:1996;226-234.
27. Murphy J., Murphy S.F. Myasthenia gravis in identical twins. Neurology. 36:1986;78-80.
28. Parren P., Warmerdam P.A.M., Boeije L.C.M., Arts J., Westerdaal N.A., Vlug A., Capel P.J., Aarden L.A., van de Winkel J.G. On the interaction of IgG subclasses with low affinity FcγRIIa (CD32) on human monocytes, neutrophils and platelets; analysis of functional polymorphism to human IgG2. J. Clin. Invest. 90:1992;1537-1546.
29. Raknes G., Skeie G.O., Gilhus N.E., Aadland S., Vedeler C. FcγRIIa and FcγRIIIb polymorphisms in myasthenia gravis. J. Neuroimmunol. 81:1998;173-176.
30. Rodriguez M.E., Van der Pol W.-L., Sanders E.A.M., Van de Winkel J.G.J. Crucial role of FcγRIIa (CD32) in assessment of functional anti-Streptococcus pneumoniae antibody activity in human sera. J. Infect. Dis. 179:1999;423-433.
31. Salmon J.E., Edberg J.C., Brogle N.L., Kimberly R.P. Allelic polymorphisms of human Fcγ receptor IIa and Fcγ receptor IIIb. Independent mechanisms for differences in human phagocyte function. J. Clin. Invest. 89:1992;1274-1281.
32. Salmon J.E., Millard S., Schachter L.A., Arnett F.C., Ginzler E.M., Gourley M.F., Ramsey-Goldman R., Peterson M.G., Kimberly R.P. FcγRIIa alleles are heritable risk factors for lupus nephritis in African Americans. J. Clin. Invest. 97:1996;1348-1354.
33. Sandor M., Lynch R.G. FcγR on T cells. Van de Winkel J.G.J., Hogarth P.M. The Immunoglobulin Receptors and Their Physiological and Pathological Roles in Immunity. 1998;169-183 Kluwer Academic Publishing, Dordrecht, The Netherlands.
34. Smyth L.J., Snowden N., Carthy D., Papasteriades C., Hajeer A., Ollier W.E. FcγRIIa polymorphism in systemic lupus erythematosus. Ann. Rheum. Dis. 56:1997;744-746.
35. Tsokos G.C., Liossis S.N.C. Immune cell signaling defects in lupus: activation, anergy and death. Immunol. Today. 20:1999;119-124.
36. Van der Pol W.-L., Van de Winkel J.G.J. IgG receptor polymorphisms: risk factors for disease. Immunogenetics. 48:1998;222-232.
37. Van der Pol W.-L., Huizinga T.W.J., Vidarsson G., van der Linden M.W., Jansen M.D., Keijsers V., Leppers-van de Straat F.G.J., Westerdaal N.A.C., van de Winkel J.G.J., Westendorp R.G.J. Relevance of FcγR and IL-10 polymorphisms for meningococcal disease. J. Infect. Dis. 184:2001;1548-1555.
38. Vincent A. Timeline: unravelling the pathogenesis of myasthenia gravis. Nat. Rev., Immunol. 10:2002;797-804.
39. Vincent A., Palace J., Hilton-Jones D. Myasthenia gravis. Lancet. 357:2001;2122-2128.
40. Warmerdam P.A.M., Van de Winkel J.G.J., Gosselin E.J., Capel P.J.A. Molecular basis for a polymorphism of human Fcγ receptor II (CD32). J. Exp. Med. 172:1990;19-25.
41. Warmerdam P.A.M., van de Winkel J.G.J., Vlug A., Westerdaal N.A.C., Capel P.J.A. A single amino acid in the second Ig-like domain of the human Fcγ receptor II is critical for human IgG2 binding. J. Immunol. 147:1991;1338-1343.
42. Wu J., Edberg J.C., Redecha P.B., Bansal V., Guyre P.M., Coleman K., Salmon J.E., Kimberly R.P. A novel polymorphism of Fcγ RIIIa (CD16) alters receptor function and predisposes to autoimmune disease. J. Clin. Invest. 100:1997;1059-1070.